Clinical stable systemic mastocytosis with interferon alpha-2b therapy

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Systemic mastocytosis (SM) is a rare neoplastic proliferation of mast cells.
• SM leads to progressive organ infiltration and has a poor prognosis with a mean survival of 2 years.
• Currently, no established therapy exists for systemic mastocytosis.

Observation:

• A patient with progressive systemic mastocytosis was treated with interferon alpha-2b.
• The treatment involved subcutaneous injections of 5 million units three times per week.
• The patient's clinical response was monitored over time.

Findings:

• The patient exhibited a significant clinical response to interferon alpha-2b therapy.
• This response remained stable for 3 years after treatment initiation.
• Observed improvements included reduced abdominal lymphadenopathy, ascites, decreased histamine levels, and improved pulmonary markings.

Implications:

• Interferon alpha-2b demonstrates potential as a therapeutic option for systemic mastocytosis.
• Sustained response suggests a role for interferon in managing aggressive SM.
• Further research into interferon-based therapies for SM is warranted.